These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

913 related items for PubMed ID: 28130918

  • 1. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S, CD1013 Study Investigators.
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [Abstract] [Full Text] [Related]

  • 2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF, Anderson CW.
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [Abstract] [Full Text] [Related]

  • 3. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R, TULIP-2 Trial Investigators.
    N Engl J Med; 2020 Jan 16; 382(3):211-221. PubMed ID: 31851795
    [Abstract] [Full Text] [Related]

  • 4. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.
    Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R.
    Ann Rheum Dis; 2018 May 16; 77(5):706-713. PubMed ID: 29420200
    [Abstract] [Full Text] [Related]

  • 5. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
    Bruce IN, van Vollenhoven RF, Psachoulia K, Lindholm C, Maho E, Tummala R.
    Lupus Sci Med; 2023 Jan 16; 10(1):. PubMed ID: 36639192
    [Abstract] [Full Text] [Related]

  • 6. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec 16; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 7. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
    Bruce IN, Furie RA, Morand EF, Manzi S, Tanaka Y, Kalunian KC, Merrill JT, Puzio P, Maho E, Kleoudis C, Albulescu M, Hultquist M, Tummala R.
    Ann Rheum Dis; 2022 Jul 16; 81(7):962-969. PubMed ID: 35580976
    [Abstract] [Full Text] [Related]

  • 8. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y, Tummala R.
    Mod Rheumatol; 2021 Jan 16; 31(1):1-12. PubMed ID: 32814461
    [Abstract] [Full Text] [Related]

  • 9. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
    Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF.
    Rheumatology (Oxford); 2022 May 05; 61(5):1900-1910. PubMed ID: 34528084
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
    Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C, EMBODY Investigator Group.
    Arthritis Rheumatol; 2017 Feb 05; 69(2):362-375. PubMed ID: 27598855
    [Abstract] [Full Text] [Related]

  • 11. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, Davis JC, Kennedy WP.
    Ann Rheum Dis; 2016 Jan 05; 75(1):196-202. PubMed ID: 26038091
    [Abstract] [Full Text] [Related]

  • 12. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF, Abreu G, Furie RA, Golder V, Tummala R.
    Ann Rheum Dis; 2023 May 05; 82(5):639-645. PubMed ID: 36690388
    [Abstract] [Full Text] [Related]

  • 13. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
    Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R.
    Ann Rheum Dis; 2022 Jul 05; 81(7):951-961. PubMed ID: 35338035
    [Abstract] [Full Text] [Related]

  • 14. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
    Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, Drappa J, Wang L, Greth W, CD1067 study investigators.
    Ann Rheum Dis; 2016 Nov 05; 75(11):1909-1916. PubMed ID: 27009916
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2018 Aug 05; 70(8):1256-1264. PubMed ID: 29671280
    [Abstract] [Full Text] [Related]

  • 16. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R, Scher F, Sagez F, Chasset F, Arnaud L.
    Drug Des Devel Ther; 2019 Aug 05; 13():1535-1543. PubMed ID: 31190735
    [Abstract] [Full Text] [Related]

  • 17. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
    Cheng LE, Amoura Z, Cheah B, Hiepe F, Sullivan BA, Zhou L, Arnold GE, Tsuji WH, Merrill JT, Chung JB.
    Arthritis Rheumatol; 2018 Jul 05; 70(7):1071-1076. PubMed ID: 29513931
    [Abstract] [Full Text] [Related]

  • 18. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
    Chia YL, Tummala R, Mai TH, Rouse T, Streicher K, White WI, Morand EF, Furie RA.
    J Clin Pharmacol; 2022 Sep 05; 62(9):1094-1105. PubMed ID: 35352835
    [Abstract] [Full Text] [Related]

  • 19. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?
    Kalunian KC.
    Lupus; 2016 Sep 05; 25(10):1097-101. PubMed ID: 27497254
    [Abstract] [Full Text] [Related]

  • 20. Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE.
    Furie R, Wang L, Illei G, Drappa J.
    Lupus; 2018 May 05; 27(6):955-962. PubMed ID: 29460699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.